IDEXX Laboratories
Market Cap
US$24.3b
Last Updated
2019/10/19 23:41 UTC
Data Sources
Company Financials +
Executive Summary
IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide.
Snowflake
Fundamentals
Proven track record with mediocre balance sheet.
Similar Companies
Share Price & News
How has IDEXX Laboratories's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
2.2%
IDXX
1.9%
US Medical Equipment
0.4%
US Market
1 Year Return
29.5%
IDXX
15.6%
US Medical Equipment
6.9%
US Market
Return vs Industry: IDXX exceeded the US Medical Equipment industry which returned 15.6% over the past year.
Return vs Market: IDXX exceeded the US Market which returned 6.9% over the past year.
Shareholder returns
| IDXX | Industry | Market | |
|---|---|---|---|
| 7 Day | 2.2% | 1.9% | 0.4% |
| 30 Day | 3.3% | -1.7% | -1.1% |
| 90 Day | -0.7% | -0.03% | -0.5% |
| 1 Year | 29.5%29.5% | 16.5%15.6% | 9.3%6.9% |
| 3 Year | 156.0%156.0% | 72.1%66.9% | 45.8%36.4% |
| 5 Year | 318.4%318.4% | 125.8%100.8% | 62.9%45.1% |
Price Volatility Vs. Market
How volatile is IDEXX Laboratories's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Is Now The Time To Look At Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?3 weeks ago | Simply Wall St
Why IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) High P/E Ratio Isn't Necessarily A Bad Thing1 month ago | Simply Wall St
Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Is Well Worth WatchingValuation
Is IDEXX Laboratories undervalued compared to its fair value and its price relative to the market?
59.99x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Undervalued: IDXX ($282.83) is trading above our estimate of fair value ($128.37)
Significantly Undervalued: IDXX is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: IDXX is poor value based on its PE Ratio (60x) compared to the Medical Equipment industry average (42.2x).
PE vs Market: IDXX is poor value based on its PE Ratio (60x) compared to the US market (17.6x).
Price to Earnings Growth Ratio
Low PEG Ratio: IDXX is poor value based on its PEG Ratio (4.8x)
Price to Book Ratio
PB vs Industry: IDXX is overvalued based on its PB Ratio (142.2x) compared to the US Medical Equipment industry average (3.8x).
Next Steps
Future Growth
How is IDEXX Laboratories forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
12.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IDXX's forecast earnings growth (12.5% per year) is above the savings rate (2.7%).
Earnings vs Market: IDXX's earnings (12.5% per year) are forecast to grow slower than the US market (14.6% per year).
High Growth Earnings: IDXX's earnings are forecast to grow, but not significantly.
Revenue vs Market: IDXX's revenue (9.6% per year) is forecast to grow faster than the US market (7.2% per year).
High Growth Revenue: IDXX's revenue (9.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: Insufficient data to determine if IDXX's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has IDEXX Laboratories performed over the past 5 years?
17.5%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: IDXX's earnings have grown by 17.5% per year over the past 5 years.
Accelerating Growth: IDXX's earnings growth over the past year (32.7%) exceeds its 5-year average (17.5% per year).
Earnings vs Industry: IDXX earnings growth over the past year (32.7%) exceeded the Medical Equipment industry 28.2%.
Return on Equity
High ROE: Whilst IDXX's Return on Equity (237.43%) is outstanding, this metric is skewed due to their high level of debt.
Return on Assets
ROA vs Industry: IDXX has a higher Return on Assets than the Medical Equipment industry average last year.
Return on Capital Employed
ROCE Improving: IDXX's Return on Capital Employed has declined over the past 3 years.
Next Steps
Financial Health
How is IDEXX Laboratories's financial position?
Financial Position Analysis
Short Term Liabilities: IDXX's short term assets ($712.3M) exceeds its short term liabilities ($618.9M)
Long Term Liabilities: IDXX's short term assets (712.3M) do not cover its long term liabilities (933.8M)
Debt to Equity History and Analysis
Debt Level: IDXX's debt to equity ratio (555%) is considered high
Reducing Debt: IDXX's debt to equity ratio has increased from 119.3% to 555% over the past 5 years.
Debt Coverage: IDXX's debt is well covered by operating cash flow (43.9%).
Interest Coverage: IDXX's interest payments on its debt are well covered by EBIT (16.1x coverage).
Balance Sheet
Inventory Level: IDXX has a high level of physical assets or inventory.
Debt Coverage by Assets: IDXX's debt is not covered by short term assets (assets are 0.7x debt).
Next Steps
Dividend
What is IDEXX Laboratories's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate IDXX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate IDXX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if IDXX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IDXX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IDXX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of IDEXX Laboratories's salary, the management and board of directors tenure and is there insider trading?
4.4yrs
Average management tenure
CEO
Jay Mazelsky (58yo)
0.3yrs
Tenure
US$2,897,125
Compensation
Mr. Jay Mazelsky is an Interim President and Chief Executive Officer of IDEXX Laboratories, Inc. since June 28, 2019. He served as an Executive Vice President of Companion Animal Group at IDEXX Laboratorie ...
CEO Compensation Analysis
Compensation vs. Market: Jay has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the US market.
Compensation vs Earnings: Jay's compensation has increased by more than 20% in the past year.
Management Age and Tenure
4.4yrs
Average Tenure
57.5yo
Average Age
Experienced Management: IDXX's management team is considered experienced (4.4 years average tenure).
Board Age and Tenure
4.9yrs
Average Tenure
57.5yo
Average Age
Experienced Board: IDXX's board of directors are considered experienced (4.9 years average tenure).
Insider Trading
Insider Buying: IDXX insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 4,000 |
| Max Price | US$271.17 |
| Entity | Individual |
| Shares | 2,300 |
| Max Price | US$274.44 |
| Entity | Individual |
| Role | Lead Director Lead Director |
| Shares | 375 |
| Max Price | US$266.41 |
| Entity | Individual |
| Role | Other Key Executive Corporate VP & GM of Global Reference Laboratories Business |
| Shares | 2,547 |
| Max Price | US$264.73 |
| Entity | Individual |
| Shares | 2,600 |
| Max Price | US$250.14 |
| Entity | Individual |
| Role | Other Key Executive Corporate VP & GM of Global Reference Laboratories Business |
| Shares | 1,812 |
| Max Price | US$245.41 |
| Entity | Individual |
| Shares | 2,015 |
| Max Price | US$250.00 |
| Entity | Individual |
| Shares | 1,500 |
| Max Price | US$211.77 |
| Entity | Individual |
| Shares | 1,373 |
| Max Price | US$212.05 |
| Entity | Individual |
| Role | Other Key Executive Corporate VP & GM of Global Reference Laboratories Business |
| Shares | 235 |
| Max Price | US$208.00 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 5,906 |
| Max Price | US$208.96 |
| Entity | Individual |
| Role | Lead Director Lead Director |
| Shares | 2,405 |
| Max Price | US$208.68 |
| Entity | Individual |
| Shares | 997 |
| Max Price | US$209.08 |
| Entity | Individual |
| Shares | 3,313 |
| Max Price | US$201.27 |
Ownership Breakdown
Management Team
Jon Ayers (63yo)
Chairman
- Tenure: 0yrs
- Compensation: US$6.82m
Brian McKeon (57yo)
CFO, Executive VP & Treasurer
- Tenure: 5.8yrs
- Compensation: US$2.91m
Jay Mazelsky (58yo)
Interim President & CEO
- Tenure: 0.3yrs
- Compensation: US$2.90m
Jeffery Chadbourne (43yo)
Senior Director of Accounting & Financial Reporting
- Tenure: 4.8yrs
Jeffrey Thomas
Corporate VP & Chief Technology Officer
- Tenure: 4.5yrs
Michael Lane
Corporate VP & GM of Global Reference Laboratories Business
- Tenure: 4.3yrs
- Compensation: US$1.36m
Kathy Turner
Corporate VP and GM of Companion Animal Group - EMEA & Asia Pacific
- Tenure: 5.4yrs
- Compensation: US$1.94m
Kerry Bennett
Vice President of Investor Relations
- Tenure: 0yrs
Ken Grady
Corporate VP & Chief Information Officer
- Tenure: 3.7yrs
John Hart
Corporate Vice President of Worldwide Operations
- Tenure: 2.1yrs
Board Members
M. Szostak (68yo)
Independent Director
- Tenure: 7.3yrs
- Compensation: US$282.53k
Dan Junius (67yo)
Independent Director
- Tenure: 5.6yrs
- Compensation: US$280.03k
Bruce Claflin (68yo)
Independent Director
- Tenure: 4.3yrs
- Compensation: US$275.03k
Stuart Essig (57yo)
Independent Director
- Tenure: 2.3yrs
- Compensation: US$260.03k
Rebecca Henderson (58yo)
Independent Director
- Tenure: 16.3yrs
- Compensation: US$270.03k
Larry Kingsley (56yo)
Lead Director
- Tenure: 1.4yrs
- Compensation: US$272.53k
Sophie Vandebroek (57yo)
Independent Director
- Tenure: 6.3yrs
- Compensation: US$260.03k
Sam Samad (49yo)
Director
- Tenure: 0.3yrs
Company Information
IDEXX Laboratories, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: IDEXX Laboratories, Inc.
- Ticker: IDXX
- Exchange: NasdaqGS
- Founded: 1983
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$24.349b
- Shares outstanding: 86.09m
- Website: https://www.idexx.com
Number of Employees
Location
- IDEXX Laboratories, Inc.
- One IDEXX Drive
- Westbrook
- Maine
- 4092
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| IDXX | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Jun 1991 |
| IX1 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jun 1991 |
| IDXX | WBAG (Wiener Boerse AG) | Yes | Common Stock | AT | EUR | Jun 1991 |
| 0J8P | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Jun 1991 |
Biography
IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and wate ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/19 23:41 |
| End of Day Share Price | 2019/10/18 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.